Abbvie Inc ABBV:NYSE

Last Price$153.80NYSE Previous Close - Last Trade as of 7:00PM ET 7/01/22

Today's Change+0.64(0.42%)
Bid (Size)$153.41 (1)
Ask (Size)$156.70 (1)
Day Low / High$151.46 - 153.86
Volume4.6 M

View Pharmaceuticals: Major IndustryPeer Comparison as of 07/01/2022


Abbvie Inc ( NYSE )

Price: $153.80
Change: +0.64 (0.42%)
Volume: 4.6 M
7:00PM ET 7/01/2022

Pfizer Inc ( NYSE )

Price: $52.31
Change: -0.12 (0.23%)
Volume: 16.1 M
7:00PM ET 7/01/2022

Eli Lilly and Co ( NYSE )

Price: $324.71
Change: +0.48 (0.15%)
Volume: 1.8 M
7:00PM ET 7/01/2022

Merck & Co Inc ( NYSE )

Price: $92.42
Change: +1.25 (1.37%)
Volume: 11.4 M
7:00PM ET 7/01/2022

Bristol-Myers Squibb Co ( NYSE )

Price: $76.84
Change: -0.16 (0.21%)
Volume: 10.9 M
7:00PM ET 7/01/2022

Read more news Recent News

AbbVie Says EMA's Committee Supports Approval of Upadacitinib for Treatment of Chronic Inflammatory Disease of the Spine
4:29AM ET 6/27/2022 MT Newswires

AbbVie (ABBV) said Monday the European Medicines Agency's Committee for Medicinal Products for Human Use has backed the approval of upadacitinib to treat...

S&P 500 Posts 6.4% Weekly Gain, Paring June's Losses After Weeks of Declines; Consumer Discretionary Leads Climb, Energy Bucks Rally
4:37PM ET 6/24/2022 MT Newswires

The Standard & Poor's 500 index rose 6.4% this week as stocks began bouncing off the previous week's lows when the market benchmark entered bear market...

--AbbVie Maintains Quarterly Dividend at $1.41 a Share, Payable Aug. 15 to Shareholders as of July 15
4:02PM ET 6/23/2022 MT Newswires

Price: 149.27, Change: -0.24, Percent Change: -0.16 ...

Morphic's Collaboration Agreement With AbbVie Biotechnology Terminated -- Shares Decline Late Hours
4:37PM ET 6/21/2022 MT Newswires

Morphic Holdings (MORF) said it received notice from AbbVie Inc.'s (ABBV) AbbVie Biotechnology terminating its Oct. 16, 2018, agreement with Morphic...

View all Commentary and Analysis

1H 2022 Portfolio Review - Avoiding A Personal Bear Market
5:36PM ET 7/01/2022 Seeking Alpha

AbbVie: Buy This Dividend King For A Growing Stream Of Income
4:28AM ET 7/01/2022 Seeking Alpha

Marketplace Roundtable - Part 6 - Biotech And Healthcare
5:24PM ET 6/30/2022 Seeking Alpha

Genmab: A Royalty Powerhouse With A Strong Pipeline
10:26AM ET 6/28/2022 Seeking Alpha

Company Profile

Business DescriptionAbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL. View company web site for more details
Address1 North Waukegan Road
North Chicago, Illinois 60064-6400
Number of Employees30,000
Recent SEC Filing06/29/20228-K
Chairman & Chief Executive OfficerRichard A. Gonzalez
Vice Chairman & PresidentRobert A. Michael
Chief Financial Officer & Senior Vice PresidentScott T. Reents
Chief Scientific Officer, Senior VP-R&DThomas J. Hudson

Company Highlights

Price Open$153.08
Previous Close$153.16
52 Week Range$105.56 - 175.91
Market Capitalization$271.8 B
Shares Outstanding1.8 B
SectorHealth Technology
IndustryPharmaceuticals: Major
Current Dividend / Yield$1.41 / 3.67%
Dividend Ex-Date07/14/2022
Dividend Pay-Date08/15/2022
Dividend Yield 5 Year Average4.08%
Next Earnings Announcement07/29/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings22.07
Earnings per Share$8.17
Beta vs. S&P 500N/A
Revenue$32.8 B
Net Profit Margin21.86%
Return on Equity85.78%

Analyst Ratings as of 06/27/2022

Consensus RecommendationConsensus Icon
Powered by Factset